Resources
18 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/5/2021 (updated 4/5/2024)
The United States is facing a crisis of opioid-related overdose. At this time, more people die of overdose every year than died of AIDS at the peak of the HIV epidemic. Communities seek effective responses to prevent opioid death.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 10/18/2021 (updated 4/3/2024)
The MOUD Best Practices Webinar series takes a person-centered, outcomes-focused approach to presenting and discussing best practices in the use of medication for opioid use disorder (MOUD), starting with client engagement and initiation of MOUD, patient stabilization and retention in MOUD, and supporting recovery during MOUD. The focus of each presentation in the series will be on the application of best practices to meet your community’s goals for each of the three topic areas, including adapting them to your local resources while maintaining fidelity to their evidence base.
At the conclusion of Session 2 participants will be able to: describe specific best practices related to stabilization and retention in MOUD, connect best practices to the community’s outcomes and goals and adapt best practices to local needs and resources while maintaining fidelity to the evidence base
Presenter: Melinda Campopiano, MD (mcampopiano@jbsinternational.com)
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 10/23/2020 (updated 4/3/2024)
This report analyzes Medicaid State Drug Utilization Data from 2011 to 2018 to track Medicaid prescriptions, unit prices, and spending after accounting for federal rebates paid by manufactures to Medicaid programs for extended-release MOUDs.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.